File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration

TitleThe use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration
Authors
Issue Date1990
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJOG
Citation
British Journal Of Obstetrics And Gynaecology, 1990, v. 97 n. 3, p. 260-266 How to Cite?
AbstractAnimal and clinical evidence suggests that the antiprogestin mifepristone may be of potential use for cervical preparation before surgical termination of pregnancy. A double-blind, multicentre study was undertaken of 230 primigravid women with 10-12 weeks amenorrhoea who were randomly assigned to groups given 0 (placebo), 25, 50 or 100 mg mifepristone twice at 24 and 12 h before vacuum aspiration. In mifepristone-treated women the cervix was on average between 0.9 and 1.2 mm more dilated at operation, but the effect was not dose related. High resistance during further mechanical stretching tended to be encountered more often and at a smaller cervical diameter in the placebo group than in the women given mifepristone, but these differences were not statistically significant. In contrast, the ease of dilatation assessed subjectively by the operating surgeons was not only improved by the antiprogestin, but was also dose related. Mifepristone therapy was not associated with any side-effects and only two of the women from the highest dose group experienced preoperative vaginal bleeding. Preoperative blood loss, post-operative complications, the duration of post-operative bleeding and the interval to the first period were similar in the four treatment groups.
Persistent Identifierhttp://hdl.handle.net/10722/173164
ISSN
2001 Impact Factor: 2.321

 

DC FieldValueLanguage
dc.contributor.authorUrquhart, DRen_US
dc.contributor.authorBahzad, Cen_US
dc.contributor.authorHubel, Ven_US
dc.contributor.authorHo, PCen_US
dc.contributor.authorCheang, Aen_US
dc.contributor.authorLundstromLindstedt, Ven_US
dc.contributor.authorHerczeg, Jen_US
dc.contributor.authorBelsey, EMen_US
dc.contributor.authorVan Look, PFAen_US
dc.date.accessioned2012-10-30T06:28:16Z-
dc.date.available2012-10-30T06:28:16Z-
dc.date.issued1990en_US
dc.identifier.citationBritish Journal Of Obstetrics And Gynaecology, 1990, v. 97 n. 3, p. 260-266en_US
dc.identifier.issn0306-5456en_US
dc.identifier.urihttp://hdl.handle.net/10722/173164-
dc.description.abstractAnimal and clinical evidence suggests that the antiprogestin mifepristone may be of potential use for cervical preparation before surgical termination of pregnancy. A double-blind, multicentre study was undertaken of 230 primigravid women with 10-12 weeks amenorrhoea who were randomly assigned to groups given 0 (placebo), 25, 50 or 100 mg mifepristone twice at 24 and 12 h before vacuum aspiration. In mifepristone-treated women the cervix was on average between 0.9 and 1.2 mm more dilated at operation, but the effect was not dose related. High resistance during further mechanical stretching tended to be encountered more often and at a smaller cervical diameter in the placebo group than in the women given mifepristone, but these differences were not statistically significant. In contrast, the ease of dilatation assessed subjectively by the operating surgeons was not only improved by the antiprogestin, but was also dose related. Mifepristone therapy was not associated with any side-effects and only two of the women from the highest dose group experienced preoperative vaginal bleeding. Preoperative blood loss, post-operative complications, the duration of post-operative bleeding and the interval to the first period were similar in the four treatment groups.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJOGen_US
dc.relation.ispartofBritish Journal of Obstetrics and Gynaecologyen_US
dc.subject.meshAbortion, Induced - Methodsen_US
dc.subject.meshAdulten_US
dc.subject.meshCervix Uteri - Drug Effectsen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Administration & Dosageen_US
dc.subject.meshMulticenter Studies As Topicen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Trimester, Firsten_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshSuctionen_US
dc.titleThe use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspirationen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2185822-
dc.identifier.scopuseid_2-s2.0-0025214549en_US
dc.identifier.volume97en_US
dc.identifier.issue3en_US
dc.identifier.spage260en_US
dc.identifier.epage266en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridUrquhart, DR=7004637703en_US
dc.identifier.scopusauthoridBahzad, C=6506602941en_US
dc.identifier.scopusauthoridHubel, V=6508311875en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.scopusauthoridCheang, A=55276616900en_US
dc.identifier.scopusauthoridLundstromLindstedt, V=6508135971en_US
dc.identifier.scopusauthoridHerczeg, J=7004223983en_US
dc.identifier.scopusauthoridBelsey, EM=35885076200en_US
dc.identifier.scopusauthoridVan Look, PFA=7005176694en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats